Regulatory FDA experts endorse Moderna’s mRNA seasonal flu shot PharmaphorumA unanimous endorsement from FDA advisors brings Moderna's RNA-based seasonal influenza vaccine a step closer to US approval.Infectious DiseaseRead full story pharminent June 19, 2026 (Last updated: June 22, 2026) Pharmaphorum A unanimous endorsement from FDA advisors brings Moderna’s RNA-based seasonal influenza vaccine a step closer to US approval. Infectious Disease Read full story Post navigation Previous: FDA’s new voucher program hints at broader policy agenda, making many ‘uncomfortable’Next: Biogen to acquire RayThera for up to $1bn Related Stories Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026 Regulatory HHS appoints permanent FDA CBER, CDER heads pharminent September 10, 2026 Regulatory FDA approves AstraZeneca’s Etcamah combo for advanced breast cancer pharminent September 7, 2026